Clinical Study Of Treatment Of Syndrome Of Stagnation Of Liver Qi And Spleen Deficiency Of Diarrhea Irritable Bowel Syndrome By Chang JiLing

ObjectiveTraditional Chinese medicine has unique advantages in the treatment of diarrhea predominant irritable bowel syndrome.This paper is based on the previous research,used a clinical research of normative randomized,placebo-controlled,double-blind method and recognized clinical curative effect index to validate and evaluate the clinical efficacy and safety of the treatment of Liver stagnation and spleen deficiency of IBS-D by Chang JiLing.MethodsA randomized,controlled,double-blind design was performed.The liver stagnation and spleen deficiency syndrome of IBS-D patients who was met the inclusion criteriawere randomly divided into treatment group and control group,treatment group received e Chang JiLingtreatment,the control group was given placebo treatment.The research is divided into the observation period,the treatment period and follow-up period,baseline observation period was 2 weeks,the treatment period was 4 weeks.the follow-up period was 3 months.The follow-up after treatment,divided into two nodes,first months and third months,the observation indexes including IBS-SSS scale,IBS-QOL scale HAMA and HAMD measuring scale change and bowel symptom diary etc.ResultsA total of 53 patients were included in the study,including the treatment group of 27 cases,the control group of 26 cases.No differences between the two groups in gender,age,course of disease,medical history,medication history and allergic history data,there is no significant difference in the IBS-SSS score,IBS-QOL score and dimensions,bowel related symptoms score and HAMA score,HAMD score at baseline,comparable.After treatment,the two groups were compared in the 'following aspects:the main efficacy index and the secondary efficacy index,the results were as follows:(a)the main efficacy index1.Comparison of IBS-SSS integral points at each pointThe total score of IBS-SSS in the treatment group was gradually decreased at baseline,fourth weeks after treatment,followed up for first months,and followed up for third months.The total score of IBS-SSS in the control group at baseline,fourth weeks after treatment,followed up for a period of first months showed a gradual downward trend,increased at the follow-up of third months.Compared with the two groups,the results of the analysis of the inter group effect,F=12.606,P=0.001,indicating that the IBS-SSS scores of the two groups were different,the treatment group was significantly better than the control group.2.Comparison of AR response rateThe response rate of the treatment group was 88.9%,and the response rate of the control group was 42.3%,the difference between the two groups was statistically significant(P<0.01).It showed that the symptoms of the treatment group were significantly lower than those of the control group.(b)Secondary efficacy index1.Comparison of IBS-QOL scoresThe IBS-QOL scores of the two groups were improved,but the treatment group was significantly better than the control group in terms of IBS-QOL scores,dysthymia,behavioral disorders,health worry,eating avoidance.2.Comparison of HAMA integral scores and HAMD integral scoresThe HAMA score and HAMD score of the two groups decreased after treatment,but there was no difference between the two groups.3.Comparison of defecation related symptom scoreTwo groups in the number of defecation score,abdominal pain score,stool traits score,mucus stool,defecation urgency scoreand defecation score of the five aspects are reduced,however,the treatment group was better than the control group in improving the stool character,mucus stool and reduce the number of the defecation.4.Comparison of IBS-SSS grade improvementAfter treatment,the effective rate of the treatment group was 81.48%,the effective rate of the control group was 42.31%,and the comparison between the two groups was statistically significant(P<0.05).The results showed that the curative effect of the treatment group was better than that of the control group.ConclusionThe treatment of liver stagnation and spleen deficiency IBS-D patients by Chang JiLing can significantly reduce the scores of IBS-SSS,improve the life quality of the patients,especially in the dimension of dysthymia,behavioral disorders,health concerns,eating escape improved obviously,and can reduce the stools and mucous,clinical application and no adverse reaction was found in clinical application.